Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [917]

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Molecular assay may help identify NSCLC patients who could benefit from...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Making immune check point inhibitors for lung cancer cost-effective in LMICs

Dr Giulia Segafredo and Dr Dario Trapani

Making immune check point inhibitors for lung cancer cost-effective in LMICs ( Dr Giulia Segafredo and Dr Dario Trapani )

ASCO 2025: Latest in EGFR positive NSCLC

Prof Pascale Tomasini, Prof Enriqueta Felip, Prof Nicolas Girard

ASCO 2025: Latest in EGFR positive NSCLC ( Prof Pascale Tomasini, Prof Enriqueta Felip, Prof Nicolas Girard )

ELCC 2025: Latest in EGFR positive NSCLC

Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna...

ELCC 2025: Latest in EGFR positive NSCLC ( Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom )

Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in...

Dr Giulia Pasello - University of Padova, Padua, Italy

Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in resectable NSCLC ( Dr Giulia Pasello - University of Padova, Padua, Italy )

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA...

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )

Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer

Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA

Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer ( Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA )

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive...

Dr Sacha Rothschild - University of Basel, Basel, Switzerland

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC ( Dr Sacha Rothschild - University of Basel, Basel, Switzerland )

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced...

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )

Treatment with BAY 2927088 led to durable responses in patients previously...

Prof Nicolas Girard - Institut Curie, Paris, France

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus...

Prof Nicolas Girard - Institut Curie, Paris, France

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced ( Prof Nicolas Girard - Institut Curie, Paris, France )

More from ecancer